We conceive, develop and test drug candidates that re-balance dysregulated immune systems by promoting pro-resolutive and decreasing pro-inflammatory signals.

The molecules we develop at IMD-Pharma have the potential to become « first-in-class » drugs for the treatment of chronic inflammatory diseases. The therapeutic efficacy of our leads has been demonstrated in several clinically recognized animal models of common CIDs, like rheumatoid arthritis (RA), psoriasis and multiple sclerosis (MS).

Drug candidates developed at IMD-Pharma are orally bioavailable, and, when required, specific formulations have been developed in collaboration with academic partners to increase skin penetration or to access the central nervous system.

Our lead investigational drug IMD-026 is currently in late non-clinical development for the treatment of RA. It is an improved version of IMD-006, which has the potential to inhibit bone resorption and cartilage destruction, turning blocked and painful joints into functional ones, while addressing systemic inflammation in a non-immunosuppressive manner.

Pipeline

IMD-026

Therapeutic domain: rheumatoid arthritis/VEXAS syndrome

Discovery

Pre-clinical

Phase 1

Phase 2

Pre-clinical

IMD-006/IMD-026

Therapeutic domain: skin inflammation

Discovery

Pre-clinical

Phase 1

Phase 2

Pre-clinical

IMD-036

Undisclosed therapeutic domain

Discovery

Pre-clinical

Phase 1

Phase 2

Discovery

Let’s get in touch

Cédric-Olivier Turrin
+33 (0)6 48 16 85 39

IMD-Pharma S.A.S.
205 route de Narbonne (LCC-CNRS)
31077 Cedex 4
FRANCE

5 + 11 =

©2023 IMD Pharma SAS - Legal notice - Privacy policy - Webdesign: sandrinetyteca.fr